Published in Mental Health Business Week, May 27th, 2006
Funding for the FDTTI is provided by the United States Congress.
Maas Biolab, LLC is developing proprietary cyclosporin formulations for the treatment of battlefield traumatic brain injury and nerve agent exposure. This FDTTI grant will speed development of these cyclosporin formulations, which are being tested at the Walter Reed Army Institute of Research (WRAIR) in Silver Spring, Maryland, by Drs. Richard A. Bauman and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Mental Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.